Particle.news
Download on the App Store
12 ARTICLES
·
10mo ago

GLP-1 Drugs Show Promise in Reducing Risk of Multiple Obesity-Linked Cancers

New research indicates that medications like Ozempic may lower the risk of developing ten specific cancers in people with type 2 diabetes.

The glucagon like peptide-1 receptor (GLPr) is a G protein–coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone. The activated receptor has a strong effect on the management of type 2 diabetes mellitus and obesity, including glucose homeostasis and regulation of gastric motility and food intake.
Ozempic medication
Image

Overview

  • The study analyzed data from 1.7 million U.S. patients over 15 years.
  • GLP-1 drugs were associated with a reduced risk for cancers such as esophageal, colorectal, and pancreatic.
  • No significant reduction in risk was observed for thyroid, stomach, or breast cancers.
  • The findings support the potential broader health benefits of GLP-1 drugs beyond diabetes and weight loss.
  • Further research is needed to confirm these results and explore additional potential applications.